SR One related stories
All articles and analysis
peHUB Wire: Tuesday, June 2, 2009Random Ramblings
- Anaphore Adds $13 Million
Anaphore Inc., a developer of protein therapeutics to address cancer and immune-mediated diseases, has raised $13 million in additional Series A funding, bringing the round total to $38 million. SR One and Merck Serono Ventures were joined by return backers 5AM Ventures, Apposite Capital and Versant Ventures.
- peHUB Wire: Friday, May 15, 2009
Random Carlyle/Cuomo Ramblings
- peHUB Wire: Friday, May 15, 2009
Random Carlyle/Cuomo Ramblings
- ProAffin Raises €14.1 Million
ProtAffin AG, an Austrian developer of drugs that target cell-surface glycan structures, has raised €14.1 million in Series B funding. Atlas Venture and S.R. One Ltd. co-led the round, and were joined by return backers Aescap Venture, Entrepreneurs Fund and Z-Cube.
- Atlas and Glaxo back Austrian biotech business
ProtAffin raises €14.1m for anti-inflammatory drug development
- Genocea Biosciences Raises $23 Million
Genocea Biosciences, a Cambridge, Mass.-based developer of prophylactic and therapeutic vaccines, has raised $23 million in Series A funding. S.R. One, the VC arm of GlaxoSmithKline, led the round, and was joined by Auriga Partners, Cycad Group and Alexandria Real Estate Equities. Returning seed backers include Lux Capital Management, Polaris Venture Partners and Morningside Ventures.
- Avantium Raises €18 Million
Avantium Technologies BV, a Dutch developer of biofuels and bioplastics, has raised €18 million in new VC funding. Aescap Venture led the round, and was joined by return backers Capricorn Cleantech Fund, ING Corporate Investments and Navitas Capital. The company has now raised over $130 million.